We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

IN RE ASACOL ANTITRUST LITIGATION

  1. March 20, 2018

    Allergan Drug Buyers Urge 1st Circ. To Keep Class Cert.

    A class of purchasers of an anti-inflammatory drug made by Allergan PLC told the First Circuit on Tuesday that a Massachusetts federal judge was right to grant them class certification in their suit claiming the pharmaceutical company illegally stifled generic competition in an effort to keep prices high.

  2. March 6, 2018

    Legal Group Urges 1st Circ. To Flip Asacol Class Cert.

    The Washington Legal Foundation on Monday backed Allergan PLC in a fight over class certification, telling the First Circuit that a Massachusetts federal judge shouldn’t have certified a class of insurers who paid for an ulcerative colitis drug without parties tied to each state involved in the product-hopping suit.

  3. January 25, 2018

    Asacol Antitrust Trial Delayed To Let Allergan Appeal Class

    The First Circuit on Thursday granted an indefinite delay of an antitrust trial slated to start next week, allowing Allergan PLC to appeal the certification of a class of unions and grocers who claim the company and a subsidiary manipulated the market with a monopolistic hard switch of available anti-inflammatory drugs.

  4. January 24, 2018

    Allergan Vies For Insurance Coverage Lists In Asacol Trial

    Allergan and Warner Chilcott on Tuesday asked a Massachusetts federal court for an order stating that lists of prescription drugs covered by insurers are admissible evidence during an antitrust trial brought by a class of organizations that purchased ulcerative colitis drug Asacol.

  5. January 8, 2018

    Allergan Fights To Keep Live Testimony In Asacol Trial

    Attorneys for Allergan PLC and subsidiary Warner Chilcott Ltd. asked a Massachusetts federal judge on Monday to block a group of unions and grocers from replacing witness testimony with recorded depositions in the antitrust class action set to go to trial in two weeks.

  6. December 5, 2017

    Buyer Class Fights Allergan Over Causation In Antitrust Row

    A class of end purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs urged a Massachusetts federal court Monday not to certify a causation issue, saying they’ve adequately argued that the companies’ alleged wrongdoing caused them harm.

  7. November 9, 2017

    Allergan Can't Nix Antitrust Row As Buyer Class Is Certified

    Allergan PLC and several related companies lost their bid to exit an antitrust suit by end purchasers of an ulcerative colitis drug as a Massachusetts federal judge on Thursday denied their attempt to kill the claims and granted certification to a class of buyers.

  8. October 6, 2017

    Attys Argue For 1/3 Slice Of $15M Asacol Deal Pie As Fees

    Attorneys for direct purchasers who recently struck a $15 million deal in a suit accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their drug Asacol urged a Massachusetts federal judge Thursday to hand them almost $5.46 million in fees and expenses, arguing that they are asking for significantly less than the $8.3 million worth of work they did in the case.

  9. September 19, 2017

    Warner Chilcott Seeks Out Of Asacol Antitrust Suit

    Allergan subsidiary Warner Chilcott has told a Massachusetts federal court that pulling its Asacol ulcerative colitis drug off the market pursuant to a federal safety order can’t be considered anti-competitive conduct, urging the court to grant it a quick win in an antitrust lawsuit.

  10. September 15, 2017

    Allergan To Pay $15M To End Asacol Antitrust Claims

    A Massachusetts federal judge Thursday granted preliminary approval to a $15 million settlement that would end claims brought by direct purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs.